Impact Capital Partners LLC purchased a new stake in shares of CorVel Co. (NASDAQ:CRVL - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 6,985 shares of the business services provider's stock, valued at approximately $777,000.
A number of other hedge funds have also added to or reduced their stakes in the stock. Boston Trust Walden Corp boosted its stake in CorVel by 196.8% during the 4th quarter. Boston Trust Walden Corp now owns 690,053 shares of the business services provider's stock valued at $76,775,000 after purchasing an additional 457,538 shares during the last quarter. State Street Corp boosted its stake in CorVel by 0.8% during the 3rd quarter. State Street Corp now owns 360,068 shares of the business services provider's stock valued at $117,703,000 after purchasing an additional 2,959 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in CorVel by 203.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 261,644 shares of the business services provider's stock valued at $29,111,000 after purchasing an additional 175,408 shares during the last quarter. Geode Capital Management LLC boosted its stake in CorVel by 3.9% during the 3rd quarter. Geode Capital Management LLC now owns 253,870 shares of the business services provider's stock valued at $83,000,000 after purchasing an additional 9,571 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in CorVel during the 4th quarter valued at about $25,123,000. Institutional investors and hedge funds own 51.36% of the company's stock.
CorVel Price Performance
Shares of NASDAQ CRVL traded up $2.55 during midday trading on Wednesday, reaching $108.34. The company's stock had a trading volume of 101,048 shares, compared to its average volume of 105,633. CorVel Co. has a 12-month low of $76.20 and a 12-month high of $128.61. The firm has a 50 day moving average price of $112.09 and a 200-day moving average price of $114.20. The stock has a market capitalization of $5.56 billion, a P/E ratio of 63.73 and a beta of 1.06.
CorVel (NASDAQ:CRVL - Get Free Report) last announced its earnings results on Tuesday, February 4th. The business services provider reported $0.46 earnings per share for the quarter. CorVel had a return on equity of 32.22% and a net margin of 10.12%.
Analysts Set New Price Targets
Separately, StockNews.com downgraded CorVel from a "buy" rating to a "hold" rating in a research note on Thursday, March 13th.
Check Out Our Latest Research Report on CRVL
Insider Transactions at CorVel
In related news, Director Alan Hoops sold 10,200 shares of CorVel stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $116.39, for a total value of $1,187,178.00. Following the sale, the director now owns 118,213 shares of the company's stock, valued at approximately $13,758,811.07. The trade was a 7.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey J. Michael sold 10,477 shares of CorVel stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $116.45, for a total transaction of $1,220,046.65. Following the completion of the sale, the director now directly owns 568,310 shares in the company, valued at $66,179,699.50. This trade represents a 1.81 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,200 shares of company stock worth $3,824,115 in the last 90 days. Insiders own 47.57% of the company's stock.
About CorVel
(
Free Report)
CorVel Corporation provides workers' compensation, auto, liability, and health solutions. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company also offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement, retrospective utilization review, facility claim review, professional review, pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services, as well as Medicare solutions.
Featured Stories
Before you consider CorVel, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorVel wasn't on the list.
While CorVel currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
